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Background: Perioperative chemotherapy for resectable squamous 
cell carcinoma of esophagus remains elusive. Thus, we assessed 
whether a perioperative regimen of paclitaxel, cisplatin, and 
5- fluorouracil (PCF) improved outcomes among patients with curable 
squamous cell carcinoma of esophagus comparing with preoperative 
chemotherapy alone.
Methods: Overall, 346 patients with resectable squamous cell carci-
noma of esophagus were randomly assigned to receive surgery plus 
perioperative chemotherapy (175, arm A) or preoperative chemo-
therapy (171, arm B). Both arms received two preoperative cycles of 
PCF: intravenous paclitaxel (100 mg per square meter of body sur-
face area) and cisplatin (60 mg per square meter of body surface area) 
on day 1, and a continuous intravenous infusion of 5- fluorouracil 
(700 mg per square meter of body surface area per day) for 5 days. 
Arm A received two added postoperative cycles of PCF. The primary 
end point was relapse-free survival, and the secondary end point was 
overall survival.
Results: Compared with preoperative chemotherapy group, perioper-
ative chemotherapy group had a greater likelihood of 5-year relapse-
free survival (hazard ratio for relapse, 0.62; 95% confidence interval, 
0.49–0.73; 31% versus 17%, p < 0.001) and of 5-year overall survival 
(hazard ratio for death, 0.79; 95% confidence interval, 0.59–0.95; 
38% versus 22%, p < 0.001). A pathologic complete response rate 
was achieved in 77 of 320 patients (24.1%) who underwent resection 
after chemotherapy. The increased PCF-related toxic events were not 
detected with the addition of two postoperative cycles of PCF.
Conclusion: In patients with operable esophageal squamous cell 
carcinoma, perioperative regimen of PCF can significantly improve 
5-year relapse-free and overall survival comparing with preoperative 
chemotherapy alone. (The trial has been registered at ClinicalTrials.
gov, number NCT01225523.)
Key Words: Perioperative chemotherapy, Preoperative chemother-
apy, Squamous cell carcinoma of esophagus, Paclitaxel, Phase III.
(J Thorac Oncol. 2015;10: 1349–1356)
With annual new diagnosis of more than 450,000, esoph-ageal cancer is characterized as the eighth most com-
mon cancer worldwide, whereas it is a highly lethal disease 
because of more than 400,000 deaths per year.1–3 The inci-
dence of esophageal adenocarcinoma is rapidly increasing, 
whereas that of squamous cell carcinoma of the esophagus 
remains unchanged.1–3 In China, esophageal cancer is the sec-
ond most common cause of cancer-related deaths in males 
and the fourth in females.4 Despite improvement in surgical 
management in the past two decades, the prognosis of patients 
with esophageal cancer undergoing resection with curable 
intent was poor with only approximately 20% survival at 5 
years.5 A huge number of patients with resectable esophageal 
cancer may shortly develop metastatic disease or local recur-
rence. The factors contribute to this dismal outlook, including 
the presence of locoregionally advanced disease, undetected 
micrometastasis at diagnosis, and inadequate preoperative 
staging. Because of high rates of locoregional and distant fail-
ure, there are increasing interests in the combination of treat-
ments with surgery.
As an alternative to resection for locoregional treatment 
of esophageal cancer, the evidences are growing to favor neo-
adjuvant chemotherapy with the potential benefits of increas-
ing the likelihood of curative resection by downstaging the 
tumor, eliminating micrometastasis, and improving survival.6,7 
In parallel, adjuvant chemotherapy has not been shown to yield 
an absolute survival benefit comparing with surgery alone 
for esophageal cancer.8–10 However, the encouraging results 
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with perioperative chemotherapy in two randomized phase III 
clinical trials were shown to significantly improve overall and 
progression-free survival in patients with the adenocarcinoma 
of stomach or esophagus,11–13 despite a divergent outcome 
from INT 113 USA trial.14,15 Conversely, a well-conceived and 
well-executed clinical trial of perioperative chemotherapy in 
patients with resectable squamous cell carcinoma of esopha-
gus remains blank.
The regimen of cisplatin and 5-fluorouracil achieved the 
response rates of 40% to 50% for squamous cell carcinoma and 
30% to 40% for adenocarcinoma.16,17 A higher histopathologic 
response rate has been detected by using more efficient cyto-
toxic agents, such as paclitaxel in patients with advanced squa-
mous cell carcinoma of esophagus.18 In the mid-1990s, there 
were considerable interests in paclitaxel for treatment of esoph-
ageal cancer with concerns on hemotologic toxic effects.18–20 In 
patients with advanced squamous cell carcinoma of esophagus, 
although the efficacy between docetaxel and paclitaxel was not 
significantly different in overall survival, paclitaxel was a more 
feasible agent with less febrile neutropenia.21 Accordingly, the 
combination of paclitaxel, cisplatin, and 5-fluorouracil (PCF) 
had substantial antitumor activity with an intriguing complete 
response rate in patients with the advanced squamous cell car-
cinoma of esophagus.18 Despite concerns regarding toxicity, 
this trial established PCF as an active chemotherapy regimen. 
given the positive findings of PCF, we sought to investigate 
whether perioperative PCF could improve the outcomes of 
resectable squamous cell carcinoma of esophagus comparing 
with those receiving preoperative PCF.
PATIENTS AND METHODS
Eligibility
The patients were enrolled at the First Affiliated Hospital 
and the Second Affiliated Hospital of Xi’an Jiaotong University 
from January 2005 to April 2007, with no evidences of previ-
ous chemotherapy or radiotherapy. Patients aged 18 years and 
older who had a World Health Organization (WHO) perfor-
mance status 0 or 1 were eligible if they had histopathologi-
cally proven squamous cell carcinoma of esophagus that was 
considered as suitable for curative resection. The disease had 
to be confined to primary and regional nodes, although celiac 
nodal involvement (M1a) was permitted for primary tumor 
localized in the distal esophagus or gastroesophageal junc-
tion. Patients had to be operative candidates without exces-
sive clinical risks and had no evidences of distant disease or 
involvement of tracheobronchial tree or other structures that 
would preclude a complete resection. Laboratory parameters 
included adequate bone marrow reserve consisting of a white 
blood cell count of more than 3500 cells/ml, platelet count of 
more than 100,000 cells/ml, normal liver function with total 
bilirubin of less than 1.5 mg/100 ml, and creatinine clearance 
of more than 60 ml/min. The protocol was approved by eth-
ics committees. The written informed consents were obtained 
before randomization.
Pretreatment examinations consisted of the followings: 
esophagogastroscopy; barium esophagram; helical computed 
tomography scans of the chest, abdomen, and pelvis; and 
exploratory laparoscopy with biopsy as indicated to confirm 
nodal disease. All the procedures were performed by experi-
enced gastroenterologists. Patients in this trial were stratified 
on the basis of clinical characteristics, including age, sex, 
WHO performance status, body weight loss, site, and maxi-
mum diameter of tumor. Pretreatment staging was not reported 
in the trial, because endocopic ultrasonography (EUS) was not 
available at the time of trial.
Treatment Plan
Eligible patients with resectable squamous cell carci-
noma of esophagus were randomly assigned to receive surgery 
plus perioperative chemotherapy (175, arm A) or preoperative 
chemotherapy (171, arm B). Each 3-week cycle consisted of 
PCF: paclitaxel (100 mg per square meter of body surface area) 
by a 3-hour intravenous infusion on day 1, cisplatin (60 mg per 
square meter of body surface area) intravenously with hydra-
tion on day 1, and 5-fluorouracil (700 mg per square meter 
of body surface area) daily through day 1 to 5 by continuous 
intravenous infusion with a double-lumen Hickman catheter. 
Both arms received surgery and two preoperative cycles of 
PCF. Arm A received two added postoperative cycles of PCF. 
One milligram of warfarin daily was recommended as pro-
phylaxis against thrombosis. All patients were premedicated 
intravenously 30 minutes before therapy with 8 to 16 mg dexa-
methasone, 300 mg cimetidine, and 50 mg diphenhydramine 
hydrochloride as standard antiemetic and antianaphylaxis. The 
patients were closely monitored for toxic effects of chemother-
apy with the use of the National Cancer Institute’s Common 
Terminology Criteria for Adverse Events, version 3.0.22
Before each cycle of chemotherapy, a complete blood 
count, blood urea nitrogen, electrolyte, serum creatinine lev-
els, and liver function were required. Dose modifications of 
PCF regimen were recommended for patients with myelosup-
pression and thrombocytopenia, and dose modifications of 
5-fluorouracil were recommended for those with stomatitis, 
hand–foot syndrome, and diarrhea. If there was an increase 
in the serum creatinine level, the creatinine clearance was 
determined and cisplatin dose was subsequently modified if 
appropriate. Cisplatin was discontinued in patients with clini-
cally significant sensory neural damage. The performance sta-
tus was assessed every 3 weeks before each chemocycle. A 
1-week treatment delay was permitted to allow recovery from 
toxicity. Dose modifications were implemented based on the 
guidelines established in RTOg 113 (http://www.rtog.org/
ClinicalTrials/ProtocolTable/StudyDetails.aspx?study=0113).
Surgery and Pathologic Examination
Surgery was scheduled within 2 to 4 weeks after 
completion of the second cycle of preoperative chemother-
apy in the two arms. Postoperative chemotherapy was initi-
ated within 5 weeks after surgery in arm A. Tumors of the 
gastroesophageal junction and the lower third of esophagus 
were resected through left side of thoracotomy alone, instead 
of transhiatal resection. In patients with poor respiratory 
reserve of forced expiratory volume in one second (FEV
1
) 
less than 80%, transhiatal approach was used. The Lewis-Ivor 
operation in the patients with tumors at the middle third of 
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esophagus were preferred, and tumors of the upper third, par-
ticularly for the patients with tumors of esophagus above aorta 
arch, were subject to three-field operation in which anasto-
mosis was performed in the neck. The lymph nodes identi-
fied by pathologists were collected in the separate boxes and 
marked according to locations. Separate sampling of subcari-
nal and celiac axis lymph nodes was recommended. Surgeons 
were asked to document the extent of dissection and to state 
whether the procedure was likely to be curative or palliative. 
Early postoperative complications were prospectively scored 
by the study coordinators.
In resected specimens, tumors were classified to patho-
logic tumor, node, metastasis stages according to American Joint 
Committee on Cancer 2013 guideline. The absence of residual 
tumor in the resected specimen, including lymph nodes, was 
defined as the pathologic complete response (pCR; stage 0).
Resection Type
Resection was classified as curative when gross tumor 
tissues were removed, and microscopical examination 
revealed the surgical margins free of tumor (R0). Resections 
were considered palliative either when microscopical exami-
nation revealed positive margins (R1: defined as tumor tissue 
at <1.0 mm from the radical, or proximal, or distal margin) or 
when there was residual local gross disease (R2).
Follow-Up and End Points
All patients were visited at the outpatient clinic at inter-
vals of 3 months during first 2 years and every 6 months for 
3 or more years. After 5 years, follow-up data were obtained 
by telephone from patients or family practitioner. Recurrence 
of disease was diagnosed at the outpatient clinic. Recurrent 
disease was classified as locoregional or distant. Whenever a 
relapse was suspected, radiologic, endoscopic, or histologic 
confirmation was compulsory. Relapse-free survival was char-
acterized as the main end point of the study, and the secondary 
end point was overall survival.
Statistical Analysis
On the basis of the results of Medical Research Council 
(MRC) Oesophageal Cancer Working Party,23 we estimated that 
5-year survival after preoperative chemotherapy and surgery 
would be 20%. The trial was designed to detect an absolute 
increase in the survival of 15% in the perioperative chemother-
apy group, with a two-sided α level of 5% and a statistical power 
of 80%, given the enrollment of 350 patients over a period of 
3 years and approximately 170 deaths. Relapse-free survival 
was calculated from randomization to the first event (i.e., local 
recurrence, distant recurrence, or death from any cause), and 
overall survival was calculated from randomization to death 
from any causes. Data on patients who were event free were 
censored on the date the patient was last seen. Kaplan–Meier 
curves for relapse-free and overall survival were compared with 
the log-rank test on the intention-to-treat basis. Hazard ratios 
were calculated with a Cox regression model including treat-
ment alone (primary analysis) and after adjustment for base-
line stratification factors by the software RevMan 5.0 Cochrane 
Collaboration. Categorical data were compared with chi-square 
test with a test for trend over ordered categories (e.g., T stage). 
All tests were two sided and unadjusted for multiple compari-
sons. The trial was overseen by an independent data monitor-
ing committee that met five times (approximately annually) to 
review accrual, safety, and efficacy data. The committee recom-
mended continuation at each review.
RESULTS
Characteristics of Patients
Between January 2005 and April 2007, of 358 patients 
enrolled into the clinical trial, 346 were eligible and randomly 
assigned to two arms, 175 to perioperative chemotherapy 
group (arm A) and 171 to preoperative chemotherapy group 
(arm B). The mean time between randomization and preop-
erative chemotherapy was 1.5 weeks for both arms. Table 1 
showed that two arms were similar in terms of age, sex, body 
weight, and WHO performance status. Accordingly, the distri-
butions of site and maximum diameter of squamous cell carci-
noma of esophagus were also well matched (Table 1) with no 
significant differences among the two arms.
TABLE 1.  Demographic and Clinical Characteristics of the 
Patients
Characteristicsa
Arm A 
(n = 175)
Arm B 
(n = 171)
Age (yr), n (%)
  <60 88 (50.3) 86 (50.2)
  60–69 56 (32.0) 53 (31.0)
  ≥70 31 (17.7) 32 (18.8)
  Median 59 59
  Range 26–89 23–90
Sex, n (%)
  Male 152 (86.8) 145 (84.8)
  Female 23 (13.2) 26 (15.2)
WHO performance status, n (%)
  0 126 (72.0) 121 (70.8)
  1 49 (28.0) 50 (29.2)
Loss of ≥10% body weight, n (%)
  ≥10% 20 (11.4) 18 (10.5)
  <10% 155 (88.6) 153 (89.5)
Tumor site, n (%)
  Upper third of esophagus 37 (21.1) 36 (21.0)
  Middle third of esophagus 52 (29.7) 50 (29.2)
  Lower third of esophagus 84 (48.0) 83 (48.5)
  gastroesophageal junction 2 (1.2) 2 (1.3)
Maximum tumor diameter (cm), n (%)
  0.0–3.9 54 (30.9) 57 (33.3)
  4.0–7.9 86 (49.1) 82 (48.0)
  8.0–11.9 31 (17.7) 23 (13.4)
  ≥12 4 (2.3) 9 (5.3)
  Median 5.5 5.5
  Interquartile range 3.0–7.0 3.0–7.0
aThere were no significant differences between groups.
WHO, World Health Organization.
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Chemotherapy
The CONSORT flow diagram has been displayed in 
Figure 1. Preoperative chemotherapy details for 346 eligible 
patients were available in both arms, 175 in arm A and 171 in 
arm B. In arm A, three patients did not initiate chemotherapy 
for the following reasons: patient request (two patients) and 
reassessment as inoperable (one patient). Two patients in arm 
B did not implement chemotherapy for the following reasons: 
patient request (one patient) and reassessment as inoperable 
(one patient). Of 341 who started preoperative treatment 
(98.5% of patients who were eligible under randomization), 
310 (157 in arm A and 153 in arm B) accomplished two pre-
operative chemotherapy cycles. With regard to not complet-
ing two preoperative cycles, the reasons were as follows: toxic 
effects (19 patients: 9 in arm A and 10 in arm B), patient 
request (6 patients: 3 in arm A and 3 in arm B), disease pro-
gression (3 patients: 1 in arm A and 2 in arm B), early cancer-
related death (2 patients: 1 in arm A and 1 in arm B), and 
detail missing (1 patient in arm A only).
A total of 310 patients (89.7% or 89.5% of patients who 
were assigned to arm A or arm B, respectively, and 91.3% 
or 90.5% of those who started chemotherapy in arm A or 
arm B, respectively) completed two cycles of preoperative 
chemotherapy, of whom 302 patients (153 in arm A and 149 
in arm B) proceeded to surgery. Of 153 patients who pro-
ceeded to surgery in arm A, 131 subsequently started post-
operative chemotherapy and 121 ultimately completed two 
postoperative chemotherapy cycles. Reasons for not proceed-
ing to postoperative chemotherapy were disease progression 
(five patients), unplanned early death (two patients), patient 
request (five patients), postoperative complications/deaths 
(seven patients), and worsening coexisting disease (three 
patients).
One hundred twenty-one (69.1%) of 175 patients in arm 
A completed all four cycles of chemotherapy, and 121 (92.4%) 
of 131 patients who underwent two preoperative chemother-
apy cycles and surgery completed postoperative treatment. 
One hundred six (31.8%) of 333 treated patients experienced 
at least grade 3/4 toxicity under preoperative chemotherapy. 
The most common grade 3/4 toxicities were granulocytope-
nia (13.2%) and lymphocytopenia (20.1%), respectively. After 
surgery, there was no significant increase in the incidence of 
grade 3 or 4 toxic effects associated with the addition of post-
operative chemotherapy (Table 2).
FIGURE 1.  CONSORT flow diagram.
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Surgery and Pathologic Findings
One hundred sixty-one patients (92.0%) underwent sur-
gery in arm A, including eight patients who did not complete 
two cycles of preoperative chemotherapy, with a median time 
from randomization to surgery of 62 days. In parallel, 159 
patients (93.0%) underwent surgery in arm B, including 10 
patients who did not complete two cycles of preoperative che-
motherapy, with a median time from randomization to surgery 
of 61 days. In Table 3, resections were curative in 264 (82.5%) 
of 320 patients undergoing esophagectomy. In terms of post-
operative pathologic tumor, node, metastasis stage, there was 
a greater proportion of stage III tumors than other stages 
(p < 0.05 by the chi-square test for trend). Surgical approaches, 
the incidence of postoperative complications, and the median 
hospital stay were similar in the two arms (Table 3), as were 
the number of deaths within 30 days after operations (two 
patients [1.2%] and three patients [1.9%], respectively, 
Table 3). Preoperative chemotherapy had the potential benefits 
of increasing the likelihood of curative resection. Intriguingly, 
the pCR was achieved in 77 of 320 patients (24.1%) who 
underwent resection after chemotherapy (Table 3).
Relapse-Free and Overall Survival
The median follow-up was 60 and 61 months in arm A 
and arm B, respectively. Before deaths, local recurrence was 
confirmed in 25 patients (14.2%) in arm A and 35 patients 
TABLE 2.  Adverse Effects Associated with Preoperative and 
Postoperative Chemotherapy
Adverse Effectsa
Preoperative  
(n = 333b), n (%)
Postoperative  
(n = 127), n (%)
Hematologic
  granulocytopenia
   grade 0, 1, or 2 289 (86.8) 109 (85.8)
   grade 3 or 4 44 (13.2) 18 (14.2)
  Lymphocytopenia
   grade 0, 1, or 2 266 (79.9) 105 (82.7)
   grade 3 or 4 67 (20.1) 22 (17.3)
  Leukopenia
   grade 0, 1, or 2 294 (88.3) 112 (88.2)
   grade 3 or 4 39 (11.7) 15 (11.8)
  Thrombocytopenia
   grade 0, 1, or 2 330 (99.1) 126 (99.2)
   grade 3 or 4 3 (0.9) 1 (0.8)
  Hemoglobinopathy
   grade 0, 1, or 2 316 (94.9) 121 (95.3)
   grade 3 or 4 17 (5.1) 6 (4.7)
  Other hematologic abnormality
   grade 0, 1, or 2 330 (99.1) 125 (98.4)
   grade 3 or 4 3 (0.9) 2 (1.6)
Nonhematologic
  Nausea
   grade 0, 1, or 2 310 (93.1) 117 (92.1)
   grade 3 or 4 23 (6.9) 10 (7.9)
  Vomiting
   grade 0, 1, or 2 313 (94.0) 117 (92.1)
   grade 3 or 4 20 (6.0) 10 (7.9)
  Neurologic effects
   grade 0, 1, or 2 319 (95.8) 122 (96.1)
   grade 3 or 4 14 (4.2) 5 (3.9)
  Skin effects
   grade 0, 1, or 2 320 (96.1) 122 (96.1)
   grade 3 or 4 13 (3.9) 5 (3.9)
  Stomatitis
   grade 0, 1, or 2 318 (95.5) 123 (96.8)
   grade 3 or 4 15 (4.5) 4 (3.2)
  Diarrhea
   grade 0, 1, or 2 323 (97.0) 121 (95.3)
   grade 3 or 4 10 (3.0) 6 (4.7)
aThere were no significant difference between groups.
bThree hundred thirty-three patients were consisted of 168 from arm A and 165 
from arm B.
FIGURE 2.  Kaplan–Meier estimates of relapse-free survival 
(A) and overall survival (B).
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(20.5%) in arm B, and distant metastasis was confirmed in 
41 patients (23.4%) in arm A and 62 patients (36.3%) in arm 
B. The median relapse-free survival and overall survival were 
23 and 29 months in arm A versus 15 and 22 months in arm 
B. Comparing with arm B, arm A had the significantly higher 
possibility of relapse-free survival (hazard ratio for relapse, 
0.62; 95% confidence interval [CI], 0.49–0.73; p < 0.001, 
Fig. 2A) and of overall survival (hazard ratio for death, 0.79; 
95% CI, 0.59–0.95; p < 0.001, Fig. 2B). Five-year relapse-
free survival rate was 35.0% (95% CI, 26.1–47.2) in arm A 
compared with 19.1% (95% CI, 15.3–28.7) in arm B. Five-
year survival rate was 38.0% (95% CI, 29.5–43.0) in arm A 
compared with 22.0% (95% CI, 16.6–29.4) in arm B. There 
was no clear evidence of heterogeneity of treatment effect in 
terms of the site and maximum diameter of the primary tumor, 
age, sex, body weight, or WHO performance status (Fig. 3).
DISCUSSION
The recent meta-analysis of the published clinical tri-
als demonstrated no benefit from neoadjuvant chemotherapy 
for resectable squamous cell carcinoma of esophagus despite 
a greater benefit for neoadjuvant chemoradiation.16,17,24 
Intriguingly, the largest and latest randomized, controlled trial 
from UK MRC in the meta-analysis showed that preoperative 
chemotherapy significantly improved survival in resectable 
squamous cell carcinoma of esophagus,7,23 which was sup-
ported by a recent randomized, controlled clinical trial of the 
patients with the squamous cell carcinoma only.25 There are no 
clear data to support the survival benefit for adjuvant chemo-
therapy in the resected squamous cell carcinoma.8 JCOg 9204 
reported that adjuvant chemotherapy significantly improved 
5-year disease-free survival up to 55% in patients with lymph 
node–positive squamous cell carcinoma of esophagus com-
pared with 45% of surgery alone,8 following a series of clini-
cal trials including JCOg 8806 and JCOg 8807.26,27 A trend 
toward improved survival from adjuvant chemotherapy was 
found in lymph node–positive patients.9 given the aforemen-
tioned data, perioperative chemotherapy appeared attractive 
research option for patients with squamous cell carcinoma of 
the esophagus.
In this randomized phase III trial, patients with resect-
able squamous cell carcinoma of esophagus, well matched in 
the terms of clinical characteristics and surgical outcomes, 
were randomly assigned to receive perioperative or preop-
erative chemotherapy plus surgery. A significant survival 
benefit for group receiving perioperative chemotherapy plus 
surgery had been demonstrated compared with group receiv-
ing preoperative chemotherapy plus surgery based on the 
regimen of PCF. An estimated improvement of 16% in 5-year 
survival rate was raised corresponding to 28% reduction in 
the risk of death. Perioperative chemotherapy was proved as 
efficient to improve relapse-free survival by approximately 
16% compared with preoperative chemotherapy alone in the 
squamous cell carcinoma of esophagus. Because this trial 
unequivocally implemented the comparison of perioperative 
versus preoperative chemotherapy, it was reasonable that a 
statistically significant benefit from the addition of postop-
erative chemotherapy was associated with the reduced risk 
of death and progression delay in operable squamous cell 
carcinoma of esophagus. Our results did a good supple-
ment for the previous reports in the MAgIC12 and FNCLCC/
FFCD trials,11 which evaluated the impact of perioperative 
chemotherapy compared with surgery alone in the adeno-
carcinoma of esophagus. We reported a similar benefit of 
FIGURE 3.  Heterogeneity of treatment effects according to the subgroup analysis. CI, confidence interval.
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5-year overall survival to the MAgIC and FNCLCC/FFCD 
trials. It suggested that perioperative chemotherapy might be 
considered as a standard care in both adenocarcinoma and 
squamous cell carcinoma of esophagus. Intriguingly, INT 
0113/RTOg 8911 with 467 patients (53% adenocarcinoma 
and 47% squamous cell carcinoma) randomized to surgery 
alone or perioperative chemotherapy plus chemotherapy dis-
played no difference in overall survival.14,15 INT 113/RTOg 
8911 was initiated two decades ago when the methods for 
diagnosis, staging, treatment delivery, and trial design issues 
(effect-size justification, statistical power, sample size, and 
study duration) that are now mainstream in study planning 
were not rigorously applied during this time. The divergence 
from INT 113/RTOg 8911 might result from the trial design, 
especially for the assignment of postoperative chemotherapy 
or radiotherapy. A second possible explanation for the nega-
tive results of INT 113/RTOg 8911 was that the regimen 
of chemotherapy was unable to destroy the residual regional 
and micrometastatic tumors with inadequate amount of cis-
platin and fluorouracil owing to the lower rate of curative 
R0 resection (63% perioperative chemotherapy versus 59% 
surgery alone) than that in our trial (82%). In most cases of 
INT 113/RTOg 8911, for patients undergoing an R1 or R2 
resection and a portion of patients with R0 resection, chemo-
therapy was given concurrently with radiation after surgery, 
so concurrent postoperative chemoradiotherapy in patients 
receiving the surgery alone might offset the advantage of 
perioperative chemotherapy. In our trial, concurrent chemo-
radiotherapy was not recommended for patients with an R1 
or R2 resection.
The true potential of chemotherapy might be under-
estimated in patients with esophageal cancer.28 greater sur-
vival benefits may be achieved by using more effective drugs 
combinations.28–30 Paclitaxel represents a promising new 
agent with remarkable antineoplastic activity against various 
human cancers.31 The activity in esophageal cancer has been 
described in the squamous cell carcinoma with the concerns 
of the increased toxicities.32–34 According to our outcomes, 
added postoperative PCF chemotherapy did not result in the 
increased incidence of adverse effects of grade 3/4 associated 
with chemotherapy, which was relatively lower than previous 
reports because of dose attenuation.18 Furthermore, comparing 
with INT 113/RTOg 8911 (38%), more patients (69.1%) with 
curable esophageal cancer received a complete postoperative 
chemotherapy in our trial. It reflected that perioperative PCF 
was acceptable and feasible in patients with the squamous cell 
carcinoma of esophagus.
Association between pCR and survival benefit has been 
confirmed tightly.35,36 Higher pCR rate could be achieved by 
using more effective drugs combinations.28–30 In our clinical 
trial, a pCR rate was achieved in 77 of 320 patients (24.1%) 
who underwent resection after two cycles of preoperative PCF. 
It was partially reasoned that the addition of paclitaxel into the 
traditional regimen of chemotherapy, cisplatin and fluorouracil, 
had an improvement of pCR with increased well-tolerated tox-
icities. The another possibility that the greater portion of clini-
cal early-stage diseases were involved in our trial contribute to 
an intriguingly high pCR rate. Chemotherapy sensitivity, PCF 
regimen, remains elusive in the resectable squamous cell carci-
noma of esophagus. The genome profiling may do a favor for us 
to explore the sensitivity of chemotherapy agents in the future. 
In context, neoadjuvant chemoradiotherapy presents a superior-
ity for pCR with the potential limitations of perioperative mor-
tality/morbidity and toxic effects.37,38 Coupled with paclitaxel’s 
radiosensitizing, paclitaxel is an ideal agent in chemoradio-
therapy. CROSS group released that preoperative chemora-
diotherapy consisting of carboplatin/paclitaxel and concurrent 
radiotherapy improved survival with acceptable adverse effect 
and in-hospital mortality among patients with resectable squa-
mous cell carcinoma of esophagus.39,40 A remarkable pCR rate 
of 29% was achieved in patients who underwent resection after 
chemoradiotherapy, especially for 45% with squamous cell 
carcinoma. Presumably, preoperative paclitaxel-based chemo-
therapy might produce the further improvement in survival and 
complete response rate with the addition of radiation in our 
clinical trial. We believe that further improvements in manage-
ment of squamous cell carcinoma of the esophagus may be 
achieved through individualization of cytotoxic and targeted 
agents within combined modality approach.
There are some limitations that need to be acknowledged 
regarding the present trial. The possible limitation of our trial 
was that fewer than 70% of patients in arm A completed all 
protocol treatment, not completing all protocol treatment pre-
dominantly owing to early disease relapse, patient request, or 
postoperative complications. Early disease relapse reflected 
the malignant biological characteristics of esophageal cancer. 
Another possible limitation was selection bias because of the 
recruitment of eligible patients. The patients enrolled into our 
trial mainly came from four provinces, including Shaanxi, 
Shanxi, gansu, and Qinghai, all of which locate in the north-
west of China with relatively lower socioeconomic and wealthy 
status in China. Therefore, this trial is unable to reflect the epi-
demiological pattern of squamous cell carcinoma of esopha-
gus. Finally, pretreatment staging was not reported in the trial, 
because EUS was not available at the time of trial in our hospi-
tal, which may be a major limitation for preoperative evaluation.
In conclusion, our results showed that perioperative che-
motherapy with the regimen of PCF improved 5-year relapse-
free and overall survival in patients with resectable squamous 
cell carcinoma of esophagus compared with preoperative che-
motherapy alone. Therefore, this treatment should be consid-
ered as an option for patients with resectable squamous cell 
carcinoma of esophagus.
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